Agonist and antagonist dual effect of the cross-linked S19 ribosomal protein dimer in the C5a receptor-mediated respiratory burst reaction of phagocytic leukocytes

Inflammation Research

Volumn 54, Issue 2, 2005, Pages 82-90

  Revollo, I ^a   Nishiura, H ^a   Shibuya, Y ^a   Oda, Y ^a   Nishino, N ^b   Yamamoto, T ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYUSHU INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

C5a receptor; Monocytes; Neutrophils; Respiratory burst reaction; S19 ribosomal protein

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; FORMYLMETHIONYLLEUCYLPHENYLALANINE; HYBRID PROTEIN; MUTANT PROTEIN; RIBOSOME PROTEIN; RIBOSOME PROTEIN S19; TETRAZOLIUM; UNCLASSIFIED DRUG; 2 (4 IODOPHENYL) 3 (4 NITROPHENYL) 5 (2,4 DISULFOPHENYL) 2H TETRAZOLIUM; 2-(4-IODOPHENYL)-3-(4-NITROPHENYL)-5-(2,4-DISULFOPHENYL)-2H-TETRAZOLIUM; COMPLEMENT C5A RECEPTOR, HUMAN; COMPLEMENT RECEPTOR; CROSS LINKING REAGENT; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; RIBOSOMAL PROTEIN S19;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DELETION MUTANT; HUMAN; HUMAN CELL; LEUKOCYTE; MONOCYTE; NEUTROPHIL; QUANTITATIVE ANALYSIS; REDUCTION; RESPIRATORY BURST; SPECTROPHOTOMETRY; CHEMISTRY; COMPARATIVE STUDY; DIMERIZATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENE DELETION; GENETICS; METABOLISM; MUTATION; PHAGOCYTOSIS; PHYSIOLOGY;

CROSS-LINKING REAGENTS; DIMERIZATION; GENE DELETION; HUMANS; LEUKOCYTES; MEMBRANE PROTEINS; MONOCYTES; MUTATION; NEUTROPHILS; PEPTIDE FRAGMENTS; PHAGOCYTOSIS; RECEPTORS, COMPLEMENT; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; RESPIRATORY BURST; RIBOSOMAL PROTEINS; TETRAZOLIUM SALTS;

EID: 16244402637     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-004-1327-4     Document Type: Article

References (36)

1. Haviland DL, McCoy RL, Whitehead WT, Akama H, Molmenti EP, Brown A et al. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J Immunol 1995; 154: 1861-9.
2. Onuma H, Masuko-Hongo K, Yuan G, Sakata M, Nakamura H, Kato T et al. Expression of the anaphylatoxin receptor C5aR (CD88) by human articular chondrocytes. Rheumatol Int 2002; 22: 52-5.
3. Gasque P, Chan P, Fontaine M, Ischenko A, Lamacz M, Gotze O et al. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol 1995; 155: 4882-9.
4. Van Epps D, Simpson S, Johnson R. Relationship of C5a receptor modulation to the functional responsiveness of human polymorphonuclear leukocytes to C5a. J Immunol 1993; 150: 246-52.
5. Babior M. Bernard. Phagocytes and Oxidative Stress. Am J Med 2000; 109: 33-44.
6. Babior B, Lambeth J, Nauseef W. The neutrophil NADPH oxidase. Arch of Biochemistry and Biophysics 2002; 397: 342-44.
7. Mollnes TE, Brekke O-L, Fung M, Fure H, Christiansen D, Bergseth G et al. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002; 100: 1869-77.
8. Robbins RA, Russ RD, Rasmussen KK, Clayton MM. Activation of the complement system in the adult respiratory distress syndrome. Am Rev Resp Dis 1987; 145: 85-9.
9. Crawford MH, Grover EL, Kolb WP, MacMahan CA, O'Rourde RA, McManus LM et al. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 1988; 78: 1449-58.
10. Weisman HF, Barton T, Leppo MK, Marcsh HC Jr, Carson GR, Concino MF et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146-51.
11. Heller T, Hennecke M, Baumann U, Gessner E, Meyer A, Baensch M et al. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J Immunol 1999; 163: 985-94.
12. Czermak B, Sarma V, Pierson C, Warner R, Huber-Lang M, Bless M et al. Protective effects of C5a blockade in sepsis. Nature Medicine 1999; 5: 788-92.
13. Nishiura H, Shibuya Y, Matsubara S, Tanase S, Kambara T, Yamamoto T. Monocyte chemotactic factor in rheumatoid arthritis synovial tissue: probably a cross-linked derivative of S19 ribosomal protein. J Biol Chem 1996; 271: 878-82.
14. Nishiura H, Shibuya Y, Yamamoto T. S19 Ribosomal Protein Cross-linked dimer causes monocyte-predominant infiltration by means of molecular mimicry to complement C5a. Lab Invest 1998; 78: 1615-23.
15. Nishiura H, Tanase S, Shibuya Y, Nishimura T, Yamamoto T. Determination of the cross-linked residues in homo-dimerization of S19 ribosomal protein concomitant with exhibition of monocyte chemotactic activity. Lab Invest 1999; 79: 915-23.
16. Yamamoto T. Molecular mechanism of monocyte predominant infiltration in chronic inflammation: Mediation by a novel monocyte chemotactic factor, S19 ribosomal protein dimer. Pathol Int 2000; 50: 863-71.
17. Shibuya Y, Shiokawa M, Nishiura H, Nishimura T, Nishino N, Okabe H et al. Identification of receptor binding sites of monocyte chemotactic S19 ribosomal protein dimer. Am J Pathol 2001; 159: 2293-301.
18. Nishimura T, Horino K, Nishiura H, Shibuya Y, Hiraoka T, Tanase S et al. Apoptotic cells of an epithelial cell line, AsPC-1, release monocyte chemotactic S19 ribosomal protein dimer. J Biochem 2001; 129: 445-54.
19. Shrestha A, Horino K, Nishiura H, Yamamoto T. Acquired immune response as a consequence of the macrophage-dependent apoptotic cell clearance and role of the monocyte chemotactic S19 ribosomal protein dimer in this connection. Lab Invest 1999; 79: 1629-42.
20. Shrestha A, Shiokawa M, Nishimura T, Nishiura H, Tanaka Y, Nishino N et al. Switch moiety in agonist/antagonist dual effect of S19 ribosomal protein dimer on leukocyte chemotactic C5a receptor. Am J Pathol 2003; 162: 1381-8.
21. Horino K, Nishiura H, Ohsako T, Shibuya Y, Hiraoka T, Kitamura N et al. A monocyte chemotactic factor, S19 ribosomal protein dimer, in phagocytic clearance of apoptotic cells. Lab Invest 1998; 78: 1615-23.
22. Tokita K, Yamamoto T. Differential role of neutrophils and monocytes during subcutaneous plasma extravasation. Lab Invest 2004; 84: 1174-84.
23. Berridge M, Tan An S. Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents. J Immunol Methods 2000; 238: 59-68.
24. Peskin A, Winterbourn C. A microtiter plate assay for superoxide dismutase using a water-soluble tetrazolium salt (WST-1). Clinica Chimica Acta 2000; 293: 57-66.
25. Konteatis ZD, Siciliano SJ, Van Riper G, Molineaux CJ, Pandya S, Fischer P et al. Development of C5a receptor antagonists: Differential loss of functional responses. J Immunol 1994; 153: 4200-5.
26. Oda Y, Nishiura H, Tokita K, Yamamoto T. Agonist and antagonist dual effect of C5a-chimera bearing S19 ribosomal protein tail on leukocyte C5a receptor. Seikagaku 2004; 74: 1112.
27. Fernandez HN, Henson PM, Otani A, Hugli TE. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin: polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a. J Immunol 1978; 120: 109-17.
28. Elola M, Fink N. Different galectins can stimulate superoxide production in human neutrophils. In: van Driessche E, Beeckmans S, Bøg-Hansen TC, editors. Lectins, Biology, Biochemistry, Clinical Biochemistry. Vol 13. Hellerup: TEXTOP, 1999. http://plab.ku.dk/tcbh/Lectins13/ElolaFink/paper.html
29. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K et al. Novel cell proliferation and cytotoxicity assays using a tetrazolium salt that produces a water-soluble formazan dye. In Vitro Toxicol 1995; 8: 187-90.
30. Wenzel-Seifert K, Lentzen H, Aktories K, Seifert R. Complex regulation of human neutrophil activation by actin filaments: dihydrocytochalasin B and botulinum C2 toxin uncover the existence of multiple cation entry pathways. J Leukoc Biol 1999; 61: 703-11.
31. Van Epps DE, Chenoweth DE. Analysis of the binding of fluorescent C5a and C3a to human peripheral blood leukocytes. J Immunol 1984; 132: 2862-7.
32. Nataf S, Davoust N, Ames RS, Barnum SR. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 1999; 162: 4018-23.
33. Thelen M, Baggiolini M. Reconstitution of cell-free NADPH oxidase from human monocytes and comparison with neutrophils. Blood 1990; 75: 2223-8.
34. Zhao X, Carnevale KA, Cathcart MK. Human monocytes use Rac1, not Rac2, in the NADPH oxidase complex. J Biol Chem 2003; 278: 40788-92.
35. Cathcart MK. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages. Contributions to atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 23-8.
36. Chenoweth DE, Goodman MG, Weigle WO. Demonstration of a specific receptor for human C5a anaphylatoxin on murine macrophages. J Exp Med 1982; 156: 912-7.